-
Silence TV
View Dr. Klaus Giese's presentation slides here
Silence News
-
17.05.12
Silence Announce New Data from Phase I Study of Atu027 RNAi Therapy
-
14.05.12
-
03.05.12
Silence’s partner, Quark Pharmaceuticals, extends Pfizer agreement to develop RNAi compound
Follow Us On Twitter
>
-
-
RNAi Therapeutics
Silence Therapeutics has created two powerful platforms and a strong pipeline to exploit the Company's impressive technological know-how and IP.
Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics to diseases with high unmet medical need.
Silence Therapeutics wants to capitalise on these, its core competencies, to bring to market the next generation of therapeutic agents (RNAi therapeutics) alongside current small molecule and biological therapies.
J Learn More >
-
RNAi Hub
The RNAi Hub is a comprehensive resource for people interested in the latest developments in RNAi Therapeutics. The RNAi Hub regroups in one location the news from the RNAi Therapeutics field, with a particular focus on the following areas of interest:
News Events Publications Companies Clinical Trials -
15.05.12
Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
-
10.05.12
-
10.05.12
-
10.05.12
International Workshop on Small RNA in Cancer Inflammation and Aging
-
A leading RNAi
therapeutics product
and technology platform
company with proprietary delivery systems.
Review Our Pipeline
>
